Skip to main content

Advertisement

SpringerLink
Log in

The Activity and Polymorphism of the PON1 in Patients with Chronic Liver Disease: a Systematic Review and Meta-analysis

  • Review Article
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Background

Liver diseases are among the ten deadliest diseases in the world. Measuring PON1 is a test to assess the degree of liver disorder. There are several preliminary studies on the rate of PON1 activity in people with liver disease, and there are differences between the results of these studies; therefore, the aim of this research work is to determine the level of PON1 activity in people with liver disease using meta-analysis.

Method

The study searched to select articles that were published electronically from 2002 to 2020, in national and international databases of SID, MagIran, Embase, ScienceDirect, Scopus, PubMed, and Web of Science (WoS).

Results

Among the articles included in the meta-analysis, the samples in the case (patients) and control groups were 807 and 2276, respectively. The mean activity of PON1 in individuals with liver disease in the case and control groups were 142.06 ± 7.7 and 272.19 ± 39.6, respectively, and this was statistically significant (P < 0.05). The mean difference analysis highlights a difference of − 2.75 ± 0.48 between the patient and control groups, indicating that liver disease significantly reduces PON1 activity.

Conclusion

The results of this study demonstrate that the polynomorphism of the PON1 is associated with an increased risk of liver disease, with lower levels of PON1 activity in people with liver disease than in healthy patients and this decrease was more in patients with liver cirrhosis than in other liver diseases. Given the importance of this gene’s activity, studies such as this could provide a promising path for better drug design and treatment in future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

Data Availability

Datasets are available through the corresponding author upon reasonable request.

References

  1. Ramana BV, Babu MSP, Venkateswarlu N. A critical study of selected classification algorithms for liver disease diagnosis. IJDMS. 2011;3(2):101–14.

    Article  Google Scholar 

  2. Ganji A, Safavi M, Nouraie S, NasseriMoghadam S, Merat S, Vahedi H, et al. Digestive and liver diseases statistics in several referral centers in Tehran, 2000–2004. Govaresh. 2006;11(1):33–8.

    Google Scholar 

  3. Lin RH. An intelligent model for liver disease diagnosis. Artif Intell Med. 2009;47(1):53–62.

  4. Taimori N, Nyri H. Cytokeratin 18 level, paraoxonase activity and lipid profile in non-alcoholic fatty liver patients in Iran. Iranian Journal of Diabetes and Metabolism. 2015;15(3):183–91 [In Persian].

    Google Scholar 

  5. Ferré N, Camps J, Prats E, Vilella E, Paul A, Figuera L, et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem. 2002;48(2):261–8.

    Article  Google Scholar 

  6. Huang JM, Huang TH, Qiu HY, Fang XW, Zhuang TG, Liu HX, et al. Effects of hepatitis B virus infection on human sperm chromosomes. World J Gastroenterol. 2003;9:736–40.

    Article  Google Scholar 

  7. Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, Chan AO, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005;54:1610–4.

  8. Garolla A, Pizzol D, Bertoldo A, Menegazzo M, Barzon L, Foresta C. Sperm viral infection and male infertility: focus on HBV, HCV, HIV, HPV, HSV, HCMV, and AAV. J Reprod Immunol. 2013;100:20–9.

    Article  Google Scholar 

  9. De BK, Majumdar D, Das D, Biswas PK, Mandal SK, Ray S, et al. Cardiac dysfunction in portal hypertension among patients with cirrhosis and non-cirrhotic portal fibrosis. Hepatol. 2003;39(3):315–9.

    Article  Google Scholar 

  10. Ćulafić Đ, Štulić M, Obrenović R, Miletić D, Mijač D, Stojković M, et al. Role of cystatin C and renal resistive index in assessment of renal function in patients with liver cirrhosis. World J Gastroenterol. 2014;20(21):6573–9.

    Article  Google Scholar 

  11. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001;21:3–16.

    Article  CAS  Google Scholar 

  12. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease. Diabetes. 2001;50:1844–50.

    Article  CAS  Google Scholar 

  13. Papatheodoridis GV, Chrysanthos N, Savvas S, Sevastianos V, Kafiri G, Petraki K, et al. Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J Viral Hepat. 2006;13:303–10.

    Article  CAS  Google Scholar 

  14. Soon DK, Pan AX, Yeo S, Ho LH, Wise SD. Fatty liver(FL) in chronic hepatitis B carriers may affect the interpretation of alanine aminotransferase (ALT) elevations. J Hepatol. 2002;36:131.

    Article  Google Scholar 

  15. Camps J, García-Heredia A, Rull A, Alonso Villaverde C, Aragones G, Beltrán-Debón R, et al. PPARs in regulation of paraoxonases: control of oxidative stress and inflammation pathways. PPAR research2012. 2012.

  16. Gupta N, Gill K, Singh S. Paraoxonases: structure, gene polymorphism & role in coronary artery disease. Indian J Med Res. 2009;130(4):361–8.

    CAS  PubMed  Google Scholar 

  17. Mackness B, Mackness M, Aviram M, Paragh G. The paraoxonases: their role in disease development and xenobiotic metabolism. Vol 6. Springer; 2008. p. 323. 

  18. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8(1):18.

    Article  Google Scholar 

  19. Marsillach J, Ferré N, Vila MC, Lligoña A, Mackness B, Mackness M, et al. Serum paraoxonase-1 in chronic alcoholics: relationship with liver disease. Clin Biochem. 2007;40(9–10):645–50.

    Article  CAS  Google Scholar 

  20. Kedage V, Muttigi MS, Shetty MS, Suvarna R, Rao SS, Joshi C, et al. Serum paraoxonase 1 activity status in patients with liver disorders. Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association. 2010;16(2):79.

    Article  Google Scholar 

  21. Marsillach J, Aragonès G, Mackness B, Mackness M, Rull A, Beltrán-Debón R, et al. Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment. Lipids Health Dis. 2010;9(1):46.

    Article  Google Scholar 

  22. Atamer A, Bilici A, Yenice N, Selek S, Ilhan N, Atamer Y. The importance of paraoxonase 1 activity, nitric oxide and lipid peroxidation in hepatosteatosis. J Int Med Res. 2008;36(4):771–6.

    Article  CAS  Google Scholar 

  23. García-Heredia A, Marsillach J, Aragonès G, Guardiola M, Rull A, Beltrán-Debón R, et al. Serum paraoxonase-3 concentration is associated with the severity of hepatic impairment in patients with chronic liver disease. Clin Biochem. 2011;44(16):1320–4.

    Article  Google Scholar 

  24. Kilic SS, Aydin S, Kilic N, Erman F, Aydin S, Celik İ. Serum arylesterase and paraoxonase activity in patients with chronic hepatitis. World J Gastroenterol. 2005;11(46):7351.

    Article  CAS  Google Scholar 

  25. Pyati AK, Halappa CK, Pyati SA. Serum basal paraoxonase 1 activity as an additional liver function test for the evaluation of patients with chronic hepatitis. Journal of clinical and diagnostic research: JCDR. 2015;9(11):BC12.

  26. Karsen H, Binici I, Sunnetcioglu M, Baran A, Ceylan M, Selek S, et al. Association of paraoxonase activity and atherosclerosis in patients with chronic hepatitis B. Afr Health Sci. 2012;12(2):114–8.

    Article  CAS  Google Scholar 

  27. Jamall S, Ishaq M, Alam JM, Hussain S, Hussain SMW. Paraoxonase activity in patients with chronic renal failure and hepatic insufficiency. Pak J Biochem Mol Biol. 2010;43(2):54–7.

    Google Scholar 

  28. Duygu F, Tekin Koruk S, Aksoy N. Serum paraoxonase and arylesterase activities in various forms of hepatitis B virus infection. J Clin Lab Anal. 2011;25(5):311–6.

    Article  CAS  Google Scholar 

  29. Jorjani, SI. Al Aghraz al Tebiyeh vaMabahes Aliyeh, correct Tajbakhsh. Vol I. Hasan Tehran, Tehran University Press; 2005. p 226 [In Persian].

  30. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44(1):27–33.

    Article  CAS  Google Scholar 

  31. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non‐alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55(6):2005–23.

  32. Festi D, Schiumerini R, Marzi L, Di Biase AR, Mandolesi D, Montrone L, Scaioli E, Bonato, G, Marchesini‐Reggiani G, Colecchia A. Review article: the diagnosis of non‐alcoholic fatty liver disease–availability and accuracy of non‐invasive methods. Aliment Pharmacol Ther 2013;37(4): 392–400.

  33. Jamali R, Merat S, Khoshnia M, Jafari E, Kalhori A, Abolghasemi H et al. Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes. World J Gastroenterol: WJG 2008;14(18):2867.

  34. She ZG, Chen HZ, Yan Y, Li H, Liu DP. The human paraoxonase gene cluster as a target in the treatment of atherosclerosis. Antioxid Redox Signal. 2001;2(16):597–632.

    Google Scholar 

  35. Precourt LP, Amre D, Denis MC, Lavoie JC, Delvin E, Seidman E, et al. The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis. 2011;214:20–36.

    Article  CAS  Google Scholar 

  36. Torun E, Gökçe S, Aydın S, Cesur Y. Serum paraoxonase activity and oxidative stress and their relationship with obesity-related metabolic syndrome and non-alcoholic fatty liver disease in obese children and adolescents. J Pediatr Endocrinol Metab. 2014;27(7–8):667–75.

    CAS  PubMed  Google Scholar 

  37. Jaganntha B, Nagarajappa K, Mallikarjuna CR, 2013. Serum paraoxonase activity, oxidative stress & lipid profile in patients with choronic liver disease. IJPBS 2013;3(1):01–06.

  38. Hashemi M, Bahari A, Hashemzehi N, Moazeni-Roodi A, Shafieipour S, Bakhshipour A, et al. Serum paraoxonase and arylesterase activities in Iranian patients with nonalcoholic fatty liver disease. Pathophysiology. 2012;19(2):115–9.

    Article  CAS  Google Scholar 

  39. Volk M, Jaklič H, Zorn B, Peterlin B. Association between male infertility and genetic variability at the PON1/2 and GSTM1/T1 gene loci. Reprod Biomed Online. 2011;23(1):105–10.

    Article  CAS  Google Scholar 

  40. Rainwater DL, Rutherford S, Dyer TD, Rainwater ED, Cole SA, VandeBerg JL, et al. Determinants of variation in human serum paraoxonase activity. Heredity. 2008;102(2):147–54.

    Article  Google Scholar 

  41. Boshtam M, Emami Razavi A, Pourfarzam M, Ani M, Naderi GA, Basati G, et al. Serum paraoxonase 1 activity is associated with fatty acid composition of high density lipoprotein. Dis Markers 2013;35(4):273–80.

  42. Reddy S. The paraoxonase gene family at the intersection of toxicology, inflammation, infection and cancer. Fielding School of Public Health, December 11, 2014.

  43. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulatio of paraoxonase (PON1) activity. Biochem Pharmacol 2005;69(4):541–50.

  44. Mahrooz A, Mackness M, Bagheri A, Ghaffari-Cherati M, Masoumi P. The epigenetic regulation of paraoxonase 1 (PON1) as an important enzyme in HDL function: The missing link between environmental and genetic regulation. Clin Biochem. 2019;73:1–10.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank the Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Funding

This study is supported by the Student Research Committee of Kermanshah University of Medical Sciences, Deputy for Research and Technology, Kermanshah University of Medical Sciences (IR) (990397). This deputy has no role in the study process.

Author information

Authors and Affiliations

  1. Department of Biostatistics, School of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran

    Nader Salari

  2. Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

    Mohsen Kazeminia

  3. Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

    Kamran Mansouri

  4. Department of Business Systems & Operations, University of Northampton, Northampton, UK

    Amin Hosseinian-Far

  5. Department of Nursing, School of Nursing and Midwifery, Kermanshah University of Medical Sciences, Kermanshah, Iran

    Masoud Mohammadi

Authors
  1. Nader Salari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohsen Kazeminia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kamran Mansouri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amin Hosseinian-Far
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masoud Mohammadi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

KM and NA and MK contributed to the design; MM contributed statistical analysis, and participated in most of the study steps. AHF and MK prepared the manuscript. MK and MM and NS assisted in designing the study, and helped in the interpretation of the study. All authors have read and approved the content of the manuscript.

Corresponding author

Correspondence to Masoud Mohammadi.

Ethics declarations

Ethics Approval and Consent to Participate

Ethics approval was received from the ethics committee of deputy of research and technology, Kermanshah University of Medical Sciences (IR.KUMS.REC.1399.200).

Consent for Publication

Not applicable.

Competing Interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Salari, N., Kazeminia, M., Mansouri, K. et al. The Activity and Polymorphism of the PON1 in Patients with Chronic Liver Disease: a Systematic Review and Meta-analysis. J Gastrointest Canc 53, 745–755 (2022). https://doi.org/10.1007/s12029-021-00699-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-021-00699-7

Keywords

Search

Navigation